Literature DB >> 20308657

Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13.

Andrea Luciani1, Gilda Ascione, Cecilia Bertuzzi, Desirè Marussi, Carla Codecà, Giuseppe Di Maria, Sarah Elisabetta Caldiera, Irene Floriani, Sabrina Zonato, Daris Ferrari, Paolo Foa.   

Abstract

PURPOSE Comprehensive geriatric assessment (CGA) is a multidimensional method used by geriatricians and oncologists to detect and evaluate multiple age-related problems and to plan and coordinate interventions. Because its main drawback is the time required, efforts have been made to evaluate screening instruments suitable for preliminarily assessing elderly patients. The main aim of this study was to establish the accuracy of the Vulnerable Elders Survey-13 (VES-13) in predicting the presence of abnormalities revealed by CGA. PATIENTS AND METHODS Patients age > or = 70 years with a histologically or cytologically confirmed diagnosis of a solid or hematologic tumor underwent both CGA and a VES-13 assessment, and the reliability and validity of VES-13 were analyzed. Results Fifty-three percent of the 419 elderly patients with cancer (mean age, 76.8 years) were vulnerable on VES-13; the rates of disabilities on CGA and activities of daily living (ADLs)/instrumental activities of daily living (IADLs) scales were 30% and 25%, respectively. The sensitivity and specificity of VES-13 were 87% and 62%, respectively, versus CGA and 90% and 70%, respectively, versus ADL/IADL scales. CONCLUSIONS On the basis of our data, VES-13 is highly predictive of impaired functional status and can thus be considered a useful preliminary means of assessing older patients with cancer before undertaking a full CGA.

Entities:  

Mesh:

Year:  2010        PMID: 20308657     DOI: 10.1200/JCO.2009.25.9978

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  46 in total

1.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

Review 2.  Challenges in the management of older patients with colon cancer.

Authors:  Efrat Dotan; Ilene Browner; Arti Hurria; Crystal Denlinger
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

3.  The importance of negative predictive value (NPV) of vulnerable elderly survey (VES 13) as a pre-screening test in older patients with cancer.

Authors:  B Castagneto; C Di Pietrantonj; I Stevani; A Anfossi; M Arzese; L Giorcelli; L Giaretto
Journal:  Med Oncol       Date:  2013-08-31       Impact factor: 3.064

4.  Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.

Authors:  Karin Ribi; Stéphanie Rondeau; Felicitas Hitz; Ulrich Mey; Milica Enoiu; Thomas Pabst; Anastasios Stathis; Natalie Fischer; Kerri M Clough-Gorr
Journal:  Support Care Cancer       Date:  2017-04-13       Impact factor: 3.603

5.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.

Authors:  Joseph M Unger; Elise Cook; Eric Tai; Archie Bleyer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

Review 6.  Treatment of colorectal cancer in the elderly.

Authors:  Monica Millan; Sandra Merino; Aleidis Caro; Francesc Feliu; Jordi Escuder; Tani Francesch
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

7.  Adjuvant radiation use in older women with early-stage breast cancer at Johns Hopkins.

Authors:  YaoYao G Pollock; Amanda L Blackford; Stacie C Jeter; Jean Wright; Ashley Cimino-Mathews; Melissa Camp; Susan Harvey; Fariba Asrari; Nancy L Schoenborn; Vered Stearns
Journal:  Breast Cancer Res Treat       Date:  2016-10-03       Impact factor: 4.872

8.  Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.

Authors:  Diana Crivellari; Kathryn P Gray; Silvia Dellapasqua; Fabio Puglisi; Karin Ribi; Karen N Price; István Láng; Lorenzo Gianni; Simon Spazzapan; Graziella Pinotti; Jean-Marc Lüthi; Richard D Gelber; Meredith M Regan; Marco Colleoni; Monica Castiglione-Gertsch; Rudolf Maibach; Manuela Rabaglio; Alan S Coates; Aron Goldhirsch
Journal:  Breast       Date:  2013-02-28       Impact factor: 4.380

9.  Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study.

Authors:  J S Gewandter; L Fan; A Magnuson; K Mustian; L Peppone; C Heckler; J Hopkins; M Tejani; G R Morrow; S G Mohile
Journal:  Support Care Cancer       Date:  2013-02-28       Impact factor: 3.603

10.  Vulnerable elders survey and socioeconomic status predict functional decline and death among older women with newly diagnosed nonmetastatic breast cancer.

Authors:  Cynthia Owusu; Seunghee Margevicius; Mark Schluchter; Siran M Koroukian; Kathryn H Schmitz; Nathan A Berger
Journal:  Cancer       Date:  2016-06-27       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.